After Citigroup and Credit Suisse gave Edwards Lifesciences (NYSE: EW) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Suraj Kalia maintained a Buy rating on Edwards Lifesciences today and set a price target of $280.00. The company’s shares closed last Tuesday at $188.62.
According to TipRanks.com, Kalia is a 4-star analyst with an average return of 2.4% and a 50.8% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Strata Skin Sciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $268.92 average price target, a 37.4% upside from current levels. In a report issued on March 27, Morgan Stanley also maintained a Buy rating on the stock with a $241.00 price target.
See today’s analyst top recommended stocks >>
Edwards Lifesciences’ market cap is currently $39.11B and has a P/E ratio of 39.70. The company has a Price to Book ratio of 15.37.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient’s heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient’s heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
